B7-33 is a linear synthetic peptide (33 amino acids) designed as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1). Extensively utilized in laboratory research, it replicates key aspects of native relaxin-2 signaling while exhibiting bias toward ERK1/2 phosphorylation with reduced cAMP activation. This profile enables detailed studies on extracellular matrix turnover, fibrotic responses, and vascular function without full activation of downstream cascades associated with native relaxin.
Produced under GMP-aligned conditions, B7-33 is supplied as lyophilized powder with comprehensive analytical verification, including sequence confirmation via mass spectrometry, purity assessment by HPLC, and a full third-party Certificate of Analysis (CoA) for each batch to ensure reproducibility in research protocols.
Key Scientific Features
- ≥99% purity verified by reverse-phase HPLC and mass spectrometry.
- Confirmed sequence matching the published B7-33 structure (single-chain relaxin-2 B-chain derivative).
- Lyophilized format optimized for stability and aseptic reconstitution.
- Batch-specific third-party CoA documenting purity, identity, content, and absence of contaminants.
- Synthesized in GMP-aligned, ISO-compliant facilities.
- Ideal for models examining biased agonism at RXFP1, antifibrotic pathways, and endothelium-dependent vascular responses.
Research-Referenced Attributes (Pre-clinical literature observations; no therapeutic claims)
- In RXFP1-expressing cell systems, B7-33 demonstrates selective activation of the pERK pathway with minimal cAMP elevation, establishing functional bias compared to native relaxin (Chem Sci, 2016; DOI: 10.1039/C5SC04754D).
- Murine myocardial infarction models show B7-33 administration associates with attenuated adverse cardiac remodeling, reduced cardiomyocyte apoptosis, decreased endoplasmic reticulum stress markers, and improved cardiac function (J Am Heart Assoc, 2020; PMID: 32295457, https://pubmed.ncbi.nlm.nih.gov/32295457/).
- Rodent organ fibrosis models (heart and lung) indicate B7-33 prevents or reverses fibrotic deposition with potency comparable to recombinant human relaxin, linked to upregulated matrix metalloproteinases and extracellular matrix remodeling (Chem Sci, 2016; DOI: 10.1039/C5SC04754D).
- Ex vivo mesenteric artery preparations reveal B7-33 enhances endothelium-dependent relaxation through endothelium-derived hyperpolarization mechanisms, replicating vasoprotective effects of relaxin-2 (Eur J Pharmacol, 2017; PMID: 28478069, https://pubmed.ncbi.nlm.nih.gov/28478069/).
Additional context on peptide receptor interactions and biased signaling appears in Peptide Sciences – Research Insights.
Why Researchers Choose Nationwide Peptides B7-33
- Matches the exact sequence and functional profile described in foundational RXFP1 bias agonism literature.
- Delivers full analytical transparency: HPLC ≥99%, MS confirmation, and downloadable batch CoA.
- Ensures batch-to-batch consistency critical for reproducible outcomes in fibrotic, cardiac, and vascular research.
- Trusted by laboratories investigating biased GPCR signaling, matrix biology, and relaxin pathway analogs.
- Available in standard research vial sizes with competitive pricing for extended protocols.
For Research Use Only. This product is supplied strictly for in vitro and in vivo laboratory investigations by qualified researchers in controlled experimental settings. Statements regarding this product have not been evaluated by the FDA. It is not intended for human consumption, injection, diagnostic use, therapeutic application, or any non-research purpose.
